Healthcare
DexCom, Inc.(DXCM)
Live Price
Offline$75.37
+0.16% today
1Y Change
-18.43%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $22.95B
- Revenue Growth
- +15.6%
- EPS Growth
- +46.6%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
DexCom, Inc. (DXCM) is a Healthcare stock with a market cap of $22.95B and listed on NASDAQ. The stock last traded around $75.37 and down 18.4% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +15.6%, EPS growth of +46.6%, a dividend yield of 0.0%. What stands out right now is revenue +15.6%, EPS +46.6%, free cash flow +70.8% with operating margin 21.4% and ROIC 18.0%. Valuation sits in the middle of the pack at P/E 24.6 and price/sales 4.8. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines DXCM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+15.6% vs +7.6% peer median
Operating Margin
Above sector median
+21.4% vs +19.4% peer median
P/E
Below sector median
24.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 30, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +15.6% and EPS at +46.6%, with operating margin around 21.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 30, 2026 | โ | +3.0% | +2.3% | +23.8% |
2026 Feb 12, 2026 | +4.6% | +7.6% | +12.3% | -1.3% |
2025 Oct 30, 2025 | +5.9% | -14.6% | -14.9% | -6.9% |
Benchmark Edge
DXCM vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DXCM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DXCM Max Drawdown
-38.75%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DXCM and SPY.
Company Overview
DexCom, Inc.
NASDAQ Global Select
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
- Leadership
- Jacob Steven Leach
- IPO Date
- Apr 14, 2005
- Employees
- 10.2k
- Street Address
- 6340 Sequence Drive
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 200 0200
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 24.6
- EV/EBITDA
- 18.0
- Price/Sales
- 4.8
- Price/Book
- 7.7
Growth
- Revenue
- +15.6%
- EPS
- +46.6%
- Free Cash Flow
- +70.8%
Profitability
- Gross Margin
- 61.8%
- Operating Margin
- 21.4%
- Net Margin
- 19.3%
- ROE
- 33.8%
- ROIC
- 18.0%
Balance Sheet
- Debt/Equity
- 0.47
- Current Ratio
- 1.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.